Cambridge University and GSK in Open Innovation Alliance
In an attempt to speed up the discovery and development of pharmaceuticals, scientists from the University of Cambridge are teaming up with GlaxoSmithKline in an open innovation collaboration initiative.
They will work together at the Stevenage Bioscience Catalyst, the UK’s first ever open innovation bioscience campus, which is next to the drug maker’s R&D hub.
The campus was created to provide a platform for scientists to collaborate without the need for exclusive contractual arrangements between partners. The idea being that innovation and success will be accelerated when the constraints imposed by commercial secrecy are removed.
Academics will be free to consult and work with their pharma colleagues. Scientists who would not normally interact will be able to forge new contacts and working relationships. Researchers will share access to equipment, expertise and specialist skills.
A Better Future for Pharma?
“This is a highly innovative way to develop publicly funded scientific research to create new medicines to treat disease, bringing together partners with shared goals and capitalizing on what each does best,” said Professor Sir Leszek Borysiewicz, Vice-Chancellor of Cambridge University.
“Cambridge is constantly searching for new and more effective ways to get its research out into the world where it can make a difference; working with our many partners, including companies such as GSK.”
It is hoped that this eagerly anticipated move will breathe new life into drug discovery. It might also act as a catalyst for other leading institutions to seek open innovation relationships.
Add your Comment
[LOGIN FIRST] if you're already a member.fields are required.